What are growth hormone peptides?
"Growth hormone peptides" is a descriptive umbrella term, not a regulatory or pharmacological classification. It is used loosely for peptides that influence the growth hormone (GH) axis — the signalling loop running from the hypothalamus to the pituitary, and from pituitary GH release to downstream IGF-1 production in the liver and other tissues.
None of the compounds usually grouped under the term are growth hormone itself. They act one step upstream, prompting the pituitary to release more of the GH a person already produces. That matters, because endogenous release stays inside the body’s own feedback loops in a way that injected GH does not.
Within the category there are meaningfully different mechanisms, and the distinction is worth holding on to when reading claims about them.
- GHRH-related signalling — analogues of growth-hormone-releasing hormone that act on the pituitary GHRH receptor (CJC-1295, tesamorelin)
- GH secretagogues — compounds acting through the ghrelin receptor GHS-R1a to trigger a GH pulse (ipamorelin)
- Compounds affecting the wider GH/IGF-1 axis — anything that shifts GH or IGF-1 levels indirectly, which is a much broader and vaguer group
CJC-1295, ipamorelin and tesamorelin at a glance
The three peptides most often discussed under this heading sit in different places on every axis that matters: mechanism, depth of human evidence, and regulatory position. Grouping them together is convenient shorthand, not a statement that the evidence behind them is comparable.
| Peptide | Class | Relationship to GH signalling | Human evidence | Regulatory context | PeptideIndex grade |
|---|---|---|---|---|---|
| CJC-1295 | GHRH analogue | Stimulates the pituitary GHRH receptor; raises GH pulse amplitude and total secretion | Limited published human pharmacology; outcome data sparse | Not FDA-approved; used off-label by some clinics; banned in sport | Moderate |
| Ipamorelin | Selective GH secretagogue (GHS-R1a agonist) | Triggers a GH pulse through the ghrelin receptor without meaningfully raising cortisol or prolactin | Early human pharmacology work; little outcome-level trial evidence | Not FDA-approved; compounding restrictions apply in the US; banned in sport | Moderate |
| Tesamorelin | Stabilised GHRH(1-44) analogue | Produces a sustained, broadly physiological rise in endogenous GH and IGF-1 | Randomised clinical trials in a defined patient population, with a licensed indication | FDA-approved for reducing excess visceral abdominal fat in HIV-associated lipodystrophy; other uses are off-label | Strong |
CJC-1295
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone. It binds the pituitary GHRH receptor and increases both the size of natural GH pulses and total GH output, rather than supplying GH directly.
The DAC terminology causes most of the confusion around it. The DAC (drug affinity complex) version attaches to serum albumin and stays active for days, producing a steady elevation; the no-DAC form, commonly labelled Modified GRF 1-29, clears within roughly half an hour and preserves a more pulsatile pattern. These behave differently enough that they should not be treated as one compound.
The published human work is largely pharmacokinetic and pharmacodynamic: it supports the claim that the compound raises GH and IGF-1 over a dosing window. What it does not do is establish clinical outcomes — there is no comparable body of randomised trial evidence showing durable changes in body composition, recovery or long-term health in healthy adults.
Ipamorelin
Ipamorelin is a pentapeptide and a growth hormone secretagogue. It works through a different receptor from the GHRH analogues — the ghrelin receptor, GHS-R1a — which is why it is described as acting on a complementary rather than an identical pathway.
Its defining property in the early literature is selectivity: it induces a GH pulse without the pronounced cortisol, prolactin and appetite effects associated with older secretagogues. That selectivity is the reason it is preferred over compounds such as GHRP-6 in most discussion, and it is a mechanistic claim that human pharmacology work broadly supports.
The limitation is depth rather than direction. Selective GH release is not itself a clinical outcome, and there is no substantial randomised trial evidence in healthy adults for the body-composition, recovery or sleep benefits attributed to it. Effects on GH also sit within a regulated feedback system, so continuous stimulation is not expected to produce an unbounded response.
Tesamorelin
Tesamorelin is a stabilised 44-amino-acid GHRH analogue, designed to resist enzymatic degradation and produce a sustained physiological increase in endogenous GH and IGF-1. Mechanistically it belongs to the same family as CJC-1295.
Where it separates sharply from the other two is evidence. Tesamorelin has been studied in randomised clinical trials in a defined patient population and carries an approved indication for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. Its profile also records a specific, well-documented limitation: visceral fat returns after the drug is discontinued, and glucose and IGF-1 warrant monitoring.
That approval is narrow and population-specific. It is evidence about tesamorelin in that indication, not evidence about GHRH analogues in general, and it says nothing about how CJC-1295 or ipamorelin would perform in healthy adults.
CJC-1295 vs ipamorelin vs tesamorelin
Set side by side, the three differ on almost every dimension except the broad direction of their effect on GH. None of them is meaningfully described as the best of the group, because they have not been studied for the same things in the same people.
- Mechanism — CJC-1295 and tesamorelin act on the GHRH receptor; ipamorelin acts on the ghrelin receptor GHS-R1a
- Pharmacology — CJC-1295 exists in a long-acting DAC form and a short-acting no-DAC form; tesamorelin is dosed daily under an approved label; ipamorelin is short-acting
- Evidence base — tesamorelin has randomised clinical trials; CJC-1295 and ipamorelin rest mainly on human pharmacology plus preclinical work
- What has actually been studied — tesamorelin for visceral adipose tissue in a specific patient group; the other two largely for their effect on GH and IGF-1 levels themselves
- Regulatory context — tesamorelin is approved for one indication; the other two are not approved for human use and are prohibited in sport
- Main uncertainty — for CJC-1295 and ipamorelin, whether raising GH translates into outcomes; for tesamorelin, how far its trial findings generalise beyond the studied population
What does the human evidence actually show?
Evidence for this category is uneven, and it is worth reading each compound separately rather than assuming the category carries a shared standard of proof. A useful way to keep it straight is to ask which rung of the evidence ladder a given claim actually stands on.
The pivotal point is that a demonstrated rise in GH or IGF-1 is a biomarker result. It shows the compound engages the intended pathway. It does not, on its own, demonstrate muscle gain, fat loss, faster recovery, better sleep or any effect on ageing.
- Mechanistic evidence — receptor binding and pathway engagement; available for all three
- Animal evidence — supportive but frequently fails to translate to humans
- Human pharmacology — measured GH and IGF-1 responses; the main human evidence for CJC-1295 and ipamorelin
- Randomised clinical trials — controlled outcome measurement; present for tesamorelin in its studied indication
- Established clinical outcomes — accepted, reproduced benefit in defined patients; narrowest tier of all here
Common claims versus what the evidence supports
Most marketing around GH peptides makes an inferential leap from “GH rises” to a desirable outcome. The claims below are common; the evidence behind them varies a great deal.
- Muscle — studied mostly as an effect on GH and IGF-1 rather than on measured lean mass in controlled trials; a durable muscle-building effect in healthy adults remains unestablished
- Fat loss — the strongest finding in this category is tesamorelin’s reduction of visceral adipose tissue in HIV-associated lipodystrophy; that result was observed in a specific population and reverses on discontinuation, and it should not be generalised to other compounds or people
- Recovery — mechanistically plausible via the GH/IGF-1 axis, but not demonstrated by controlled human outcome trials for these peptides
- Sleep — GH secretion is closely tied to slow-wave sleep and improved sleep is widely reported anecdotally; objective controlled evidence for these specific compounds is thin
- Ageing and longevity — no human outcome evidence supports anti-ageing or lifespan claims for any of the three; the relationship between the GH/IGF-1 axis and ageing is contested rather than settled
- Body composition — changes in biomarkers are not the same as measured changes in fat and lean mass, and the two are routinely conflated
Which growth hormone peptide has the strongest evidence?
Judged purely by depth of human evidence, tesamorelin is the only one of the three with randomised clinical trial support and an approved indication. That is a real distinction and not a close call.
It is also a narrower answer than it first appears. Its evidence is for one outcome — visceral adipose tissue — in one population, and strength of evidence is always specific to an outcome and a group of people. Tesamorelin having strong evidence for that indication tells you nothing about how it would perform for recovery or body composition in a healthy adult, and nothing at all about the other two compounds.
For CJC-1295 and ipamorelin, the honest position is that the mechanism is reasonably well characterised and the outcomes are not. Both are graded Moderate on PeptideIndex on that basis. Neither the category label nor a shared effect on GH transfers tesamorelin’s trial evidence across to them.
Frequently asked questions
- What are growth hormone peptides?
- It is an umbrella term for peptides that influence the growth hormone axis, usually by prompting the pituitary to release more of a person’s own GH rather than supplying GH itself. It is a descriptive category rather than a regulatory classification, and it covers different mechanisms — GHRH analogues such as CJC-1295 and tesamorelin, and ghrelin-receptor secretagogues such as ipamorelin.
- What is the difference between CJC-1295 and ipamorelin?
- They raise GH through different receptors. CJC-1295 is a GHRH analogue acting on the pituitary GHRH receptor, while ipamorelin is a selective agonist at the ghrelin receptor GHS-R1a. Because the pathways are complementary rather than identical, the two are often discussed together rather than as substitutes for one another.
- How does tesamorelin differ from CJC-1295?
- Both are GHRH analogues, so mechanistically they are close relatives. The difference is evidence and regulatory status: tesamorelin is a stabilised GHRH(1-44) analogue studied in randomised clinical trials and approved for reducing excess visceral abdominal fat in HIV-associated lipodystrophy, while CJC-1295 is not approved for human use and is supported mainly by human pharmacology data.
- Which growth hormone peptide has the most human evidence?
- Tesamorelin, by a clear margin, because it has randomised clinical trial data and a licensed indication. That evidence is specific to one outcome in one patient population, however, and does not extend to other uses, other populations, or to CJC-1295 and ipamorelin.
- Are growth hormone peptides approved medicines?
- Only in part. Tesamorelin holds an approved indication for HIV-associated lipodystrophy; any other use of it is off-label. CJC-1295 and ipamorelin are not approved for human use, are subject to compounding restrictions in the US, and are prohibited in competitive sport.